Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Challenging Cases in the Clinic

How confident are you at identifying patients with hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence? Credit available for this activity expires: 11/28/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/983866?ecd=bdc_podcast_libsyn_mscpedu